Skip to main content
    R

    Rapport Therapeutics, Inc. Common Stock (RAPP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $24.82
    -1.33 (-5.09%)

    Market Cap: $1.55B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rapport Therapeutics, Inc. Common Stock (RAPP) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Rapport Therapeutics, Inc. Common Stock (RAPP) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Rapport Therapeutics, Inc. Common Stock reported EPS of -$0.84, above the -$1.21 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    70%(7/10)
    Avg Surprise
    -6.63%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.03
    Range-$1.51 - -$0.84
    18 analysts
    Revenue Consensus
    $7.28K
    RangeN/A
    17 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.93
    Range-$1.20 - -$0.78
    7 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.33+30.2%
    60d ago-$1.33+30.2%
    30d ago-$1.27+26.6%
    7d ago-$1.09+14.8%
    Current-$0.93
    Revenue Consensus
    N/A
    RangeN/A
    8 analysts

    Next Report

    RAPP has an expected report date of Mar 8, 2027.

    Earnings History

    Of the 10 quarters below that had an estimate, RAPP beat 7 and missed 3. The widest gap in the table came in the quarter ended Jun 30, 2024, when EPS landed 150.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.84-$1.21-$1.36 - -$1.08+30.58%BeatN/A120 up, 3 downNov 4, 2026
    Jun 30, 2026-$1.19-$0.93-$1.04 - -$0.90-27.96%MissN/A71 up, 4 downAug 5, 2026
    Mar 31, 2026-$0.42-$0.71-$1.06 - -$0.45+40.85%BeatN/A63 up, 1 downMay 7, 2026
    Dec 31, 2025-$0.72-$0.67-$0.82 - -$0.55-6.78%MissN/A71 up, 0 downMar 10, 2026
    Sep 30, 2025-$0.71-$0.73-$0.87 - -$0.63+2.74%BeatN/A51 up, 1 downNov 6, 2025
    Jun 30, 2025-$0.75-$0.87N/A+13.79%BeatN/A31 up, 0 downAug 7, 2025
    Mar 31, 2025-$0.68-$0.74N/A+8.11%BeatN/A20 up, 1 downMay 8, 2025
    Dec 31, 2024-$0.57-$0.70N/A+18.57%BeatN/A30 up, 0 downMar 11, 2025
    Sep 30, 2024-$0.50-$0.52N/A+3.85%BeatN/A30 up, 0 downNov 7, 2024
    Jun 30, 2024-$1.70-$0.68N/A-150.00%MissN/AN/AN/AAug 8, 2024
    Mar 31, 2024-$1.12N/AN/AN/AN/AN/AN/AN/AMay 29, 2024
    Last 11 quarters

    Annual EPS

    Fiscal year endedEPSChange
    Sep 30, 2026-$2.45N/A
    Jun 30, 2026-$1.61N/A
    Dec 31, 2025-$2.86N/A
    Dec 31, 2024-$3.89N/A

    Frequently Asked Questions About RAPP

    When is Rapport Therapeutics, Inc. Common Stock's next earnings date?

    Rapport Therapeutics, Inc. Common Stock's next earnings report is expected for Mar 8, 2027.

    Did RAPP beat earnings estimates last quarter?

    Yes. Rapport Therapeutics, Inc. Common Stock reported EPS of -$0.84 for the quarter ended Sep 30, 2026, above the -$1.21 estimate, a 30.58% surprise.

    What EPS do analysts expect from RAPP next quarter?

    The consensus EPS estimate for Rapport Therapeutics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$1.03 from 18 analysts, with estimates from -$1.51 to -$0.84.

    How often does RAPP beat earnings estimates?

    Rapport Therapeutics, Inc. Common Stock beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +9.99%.